Emerging data from clinical trials points to potentially powerful use of psilocybin for the treatment of depression and certain forms of addiction, and perhaps compulsive disorders, too.
One of the key questions to arise from those studies is: "what is the relationship between the actual journey (the subjective experience under the influence of psilocybin) and the improvements in mood and other thought patterns that persist afterwards"?
If you think about it, this is a critical issue to resolve because it needn't be the case that the actual journey and insights therein are the cause of the antidepressant effects. The rewiring (neuroplasticity) events in the brain could, for instance, occur afterwards or be independent of the subjective experience of the journey. Or they could simply be the consequence of the serotonin receptor activation and strengthening of certain neural connections, or even neurogenesis.
During the Huberman Lab episode out now, I discuss the data related to all of these issues. I also discuss safety considerations, and who should absolutely avoid psilocybin, which, of course are critical issues.
hubermanlab.com/how-psilocyb…